logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Lawrence Y Fang

This inventor holds 26 USPTO granted patents, primarily in Alzheimer's Disease Treatment. Top assignees: Elan Pharmaceuticals, Inc., Lafarge Coppee, Orsan. Active years: 1985-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lawrence Y Fang. Retrieved from https://idiyas.com/inventor/lawrence-y-fang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 26

% Patents Active = 61.5

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 120(Granted Patents)


Location History:

  • Daly City, CA (US) (1985 - 1988)
  • Foster, CA (US) (1994)
  • South San Francisco, CA (US) (1996)
  • Foster City, CA (US) (1988 - 2008)

Company Filing History:

goldMedal11 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
silverMedal4 out of 8 
 
Lafarge Coppee
 patents
bronzeMedal3 out of 7 
 
Orsan
 patents
4. 3 out of 3 
 
Orsem
 patents
5. 1 out of 35 
 
Athena Neurosciences, Inc.
 patents
6. 1 out of 4,520 
 
Eli Lilly and Company
 patents
7. 1 out of 1 
 
Hybrinova S.a.
 patent
8. 1 out of 117 
 
Pharmacia & Upjohn
 patents
9. 1 out of 523 
 
Pharmacia & Upjohn Company
 patents
10. 6 out of 834,659 
Other
 patents
where one patent can have more than one assignee

Years Active: 1985-2008

Loading Chart...
Areas of Expertise:
Alzheimer's Disease
Dipeptide Inhibitors
β-Secretase
Amino Acid Esters
Tetrapeptide Inhibitors
Pharmaceutical Compositions
Pollen Suppressants
Fused Pyridazine
26 patents (USPTO):Explore Patents
1. 7432389 - Compounds for the treatment of Alzheimer's disease (2008-10-07),
2. 7276484 - Dipeptide inhibitors of β-secretase (2007-10-02),
3. 7214715 - Compounds to treat Alzheimer's disease (2007-05-08),
4. 7176242 - N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives (2007-02-13),
5. 7169759 - Tetrapeptide inhibitors of β-secretase (2007-01-30),
6. 7119085 - Methods to treat alzheimer's disease (2006-10-10),
7. 7034182 - Compounds to treat Alzheimer's disease (2006-04-25),
8. 7030239 - Compounds to treat Alzheimer's disease (2006-04-18),
9. 6992081 - Compounds to treat Alzheimer's disease (2006-01-31),
10. 6864240 - Dipeptide inhibitors of β-secretase (2005-03-08),
11. 6767918 - N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2004-07-27),
12. 6737420 - Compounds to treat Alzheimer's disease (2004-05-18),
13. 6642261 - N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-11-04),
14. 6333351 - N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2001-12-25),
15. 6313152 - N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2001-11-06),

Title: Innovations in Alzheimer's Treatment by Lawrence Y Fang

Introduction

Lawrence Y Fang, a prominent inventor based in Foster City, CA, has made significant contributions to the field of medical research, particularly in the treatment of Alzheimer's disease. With a remarkable portfolio of 26 patents, Fang has dedicated his career to developing innovative compounds and methods to combat neurodegenerative diseases.

Latest Patents

Fang's latest patents include groundbreaking inventions focused on the treatment of Alzheimer's disease. One notable patent describes substituted amines of a specific formula, which are useful in treating Alzheimer's and similar diseases. Additionally, he has developed dipeptide inhibitors of β-secretase, which target the β-secretase enzyme and are beneficial in treating Alzheimer’s disease. These compounds aim to reduce Aβ peptide formation, providing useful methods of treatment via pharmaceutical compositions.

Career Highlights

Throughout his distinguished career, Lawrence Y Fang has contributed to the advancement of therapeutic solutions for complex neurological conditions. His work at companies such as Elan Pharmaceuticals, Inc. has showcased his expertise and commitment to medical research and innovation.

Collaborations

Fang has collaborated with esteemed colleagues such as Varghese John and Andrea Gailunas, fostering an environment of innovation and creativity in the development of new treatments. These collaborations have enabled the translation of research findings into viable medical therapies.

Conclusion

Lawrence Y Fang's relentless pursuit of innovation in the treatment of Alzheimer's disease has made him a key figure in medical research. His extensive patent portfolio and collaborative efforts highlight the importance of continued research and development in the battle against neurodegenerative diseases. The advancements he has championed pave the way for new therapeutic strategies and bring hope to those affected by Alzheimer's disease.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…